Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07354516 · ClinicalTrials.gov registry record · Phase 2
Study of QLS-111-FDC in Open-Angle Glaucoma or Ocular Hypertension
A Phase 2 study of OHT - Ocular Hypertension and OAG - Open-Angle Glaucoma, sponsored by Qlaris Bio.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 36
- Enrollment target
- 1
- Study location
NCT07354516 is a Phase 2 study of OHT - Ocular Hypertension and OAG - Open-Angle Glaucoma that is actively recruiting participants, run by Qlaris Bio. The registered enrollment target is 36 participants. The trial reports 1 study location across 1 state.
The verdict
NCT07354516, a Phase 2 study of OHT - Ocular Hypertension and OAG - Open-Angle Glaucoma, is actively recruiting participants, sponsored by Qlaris Bio.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 36 participants
- Enrollment target
- 1
- Study location
Study Summary
Firecrest study is evaluating the intraocular pressure (IOP)-lowering effect, safety, and tolerability of Qlaris' preservative free \[PF\], fixed-dose combination \[FDC\] investigational product (IP) in subjects with open-angle glaucoma (OAG) or ocular hypertension (OHT).
Conditions Studied
Interventions
- COMBINATION_PRODUCT QLS-111-FDC
- DRUG Latanoprost (0.005%)
Study Locations (1)
Florida
- Shettle Eye Research - Largo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2026-03-18 |
| Est. Completion | 2026-07-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07354516
The ClinicalTrials.gov registry entry for NCT07354516 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Qlaris Bio, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with OHT - Ocular Hypertension appearing as the primary indexed condition, and to 2 interventions - of which QLS-111-FDC is the first listed.
NCT07354516 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT07354516 about?
NCT07354516 is a clinical study titled "Study of QLS-111-FDC in Open-Angle Glaucoma or Ocular Hypertension". Firecrest study is evaluating the intraocular pressure (IOP)-lowering effect, safety, and tolerability of Qlaris' preservative free \[PF\], fixed-dose combination \[FDC\] investigational product (IP) in subjects with open-angle glaucoma (OAG) or ocular hypertension (OHT).
What is the current status of trial NCT07354516?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 36 participants. The study started on 2026-03-18. Estimated completion is 2026-07-15.
What conditions does trial NCT07354516 study?
This clinical trial studies the following conditions: OHT - Ocular Hypertension, OAG - Open-Angle Glaucoma.
What interventions are being tested in trial NCT07354516?
The interventions under investigation include: QLS-111-FDC (COMBINATION_PRODUCT), Latanoprost (0.005%) (DRUG).
Who is sponsoring clinical trial NCT07354516?
This trial is sponsored by Qlaris Bio, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07354516 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for OHT - Ocular Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.